维普期刊资源整合服务平台（V6.5）

532篇 您的检索式：作者名="Pao W"

选中清除导出查看参考文献查看引证文献引用追踪共27页首页上一页第1页下一页末页 /27 跳转

	题名	作者	年代	出处	被引量
1	Low temperature growth of ultrananocry stalline diamond film and its field emission properties显示文摘	Pradhan D Lee Y C Pao C W	2006	Diamond Related Mater2006，15，1112：	1
2	EGF receptor genc mu- tations are common in lung cancers from' never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib显示文摘	Pao W Miller V Zakowski M	2004	Proc Natl Acad Sci USA2004，101，13：	1
3	Clinical definition of ac-quired resistance to epidermal growth factor receptor tyrosine ki-nase inhibitors in non-small-cell lung cancer显示文摘	Jackman D Pao W Riely G J		0，，2：	1
4	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions显示文摘	PAO W MILLER VA	2005	J Clin Oncol2005，23，11：	1
5	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
6	EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to Gefitinib and erlotinib显示文摘	PAO W MILLER V ZAKOWSKI M	2004	Proc Natl Acad Sci U S A2004，101，13：	1
7	Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFRGene 显示文摘	Rizvi NA Rusch V Pao W	2011	ClinCancerRes2011，17，10：	1
8	High dose weekly erlotinib a- chieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor recep- tor mutant lung cancer显示文摘	Clarke JL Pao W Wu N	2010	J Neurooncol2010，99，2：	1
9	Acoustoelasticity and ultrasonic measurement of residual stress显示文摘	Pao Y H Sachse W	1984	Physical Acoustics1984，，17：	1
10	A protein knockdown strategy to study the function of beta -catenin in tumorgenesis显示文摘	Cong F Zhang J Pao w	2003	BMC Mol Bio2003，58，2：	1
11	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer显示文摘	Jackman D Pao W Riely GJ ct al	2010	J Clin Oncol2010，28，2：	1
12	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib显示文摘	Pao W Wang TY Riely GJ	2005	PLoS Med2005，，：	1
13	KRAS mutations andprimary resistance of lung adenocarcinomas to gefitinib or erlotinib显示文摘	Pao W Wang TY Riely GJ et a1		0，，01：	1
14	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	PAO W MILLER V A POLITI K A	2005	PloS Med2005，2，3：	1
15	Core needle lung biopsy specimens:adequacy for EGFR and KRAS mutational analysis显示文摘	Solomon SB Zukowski MF Pao W	2010	AJR2010，194，：	1
16	Clinical course of patients withnon-small cell lung cancer and epidermal growth factor receptorexon 19 and exon 21 mutations treated with gefitinib or erlotinib显示文摘	Riely GL Pao W Plam D	2006	Clin Cancer Res2006，12，31：	1
17	EML4-ALK:Honing in on a new target in nonsmall-cell lung cancer显示文摘	Horn L Pao W		0，，26：	1
18	Epidermal growth factor receptor mutations,small molecule kinase inhibitors,and non-small-cell lung cancer: current knowledge and future directions 显示文摘	Pao W Miller VA	2005	J Clin Oncol2005，23，11：	1
19	New driver mutations in non-small-cell lung cancer显示文摘	Pao W Girard N	2011	Lancet Oncol2011，12，2：	1
20	Clinical definition of acquired resistance to epidermal growth factor receptor ty- rosine kinase inhibitors in non-small-cell lung cancer显示文摘	Jackman D Pao W Riely GJ	2010	J Clin Oncol2010，28，2：	1

返回顶部每页显示：

共27页首页上一页第1页下一页末页 /27 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示